HomeAI · summaries
Storia in 3 fonti
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?
Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver of this improved performance.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Wockhardts newly approved antibiotic Zaynich has the potential to transform the treatment of drug-resistant infections, according to Mahesh Patel, the scientist behind the drug.…
- ·
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…
- ·
thehindubusinessline.com
Wockhardt marks research milestone with USFDA approval for novel antibiotic Zaynich
Zaynich (cefepime and zidebactam) is an injectable antibiotic comprising cefepime, a cephalosporin antibacterial drug and zidebactam, a non-β-lactam antibacterial and β-lactamase…
- ·
If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala
Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual…
- ·
timesofindia.indiatimes.com
'USFDA nod for Zaynich a major boost'
NEW DELIH: The US Food and Drug Administration's approval of Wockhardt's Zaynich, a first-in-class 'breakthrough antibiotic' for severe drug-resistant infections, opens up a…
- ·
Zaynich's blockbuster potential lifts Wockhardt's long-term outlook
Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting…
- ·
Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract…
- ·
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?
Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company…